Literature DB >> 14716760

Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma.

Ferdinando De Vita1, Michele Orditura, Eva Lieto, Stefania Infusino, Floriana Morgillo, Erika Martinelli, Paolo Castellano, Ciro Romano, Fortunato Ciardiello, Giuseppe Catalano, Carlo Pignatelli, Gennaro Galizia.   

Abstract

BACKGROUND: To the authors' knowledge, little is known to date regarding the prognostic relevance of measuring serum levels of vascular endothelial growth factor (VEGF), a potent stimulator of angiogenesis, in patients with colon carcinoma who undergo surgery.
METHODS: Preoperative and postoperative VEGF serum levels were determined by enzyme-linked immunoadsorbent assay in 81 patients with colon carcinoma who were undergoing surgery. Fifty healthy individuals served to define normal VEGF serum levels.
RESULTS: Preoperative VEGF serum levels were significantly higher in the group of patients with colon carcinoma (mean, 504.1 pg/mL +/- 223 pg/mL; range, 285-1390 pg/mL; 95% confidence interval [95%CI], 49 pg/mL) compared with the control group (mean, 78.1 pg/mL +/- 22 pg/mL; range, 40-110 pg/mL; 95%CI, 4.3 pg/mL; P < 0.001). Multiple regression analysis demonstrated a significant correlation (r) between preoperative VEGF serum levels and age (r = - 0.275; P = 0.013), Dukes stage (r = 0.488; P < 0.001), and carcinoembryonic antigen (CEA) levels (r = 0.285; P < 0.018). No significant correlation was found between preoperative VEGF serum levels and disease site, patient gender, tumor size, tumor grade, or performance status. Moreover, preoperative VEGF serum levels were significantly lower in patients who underwent curative surgery compared with patients who underwent noncurative surgery (443 pg/mL +/- 117 pg/mL vs. 821 +/- 353 pg/mL, respectively; P < 0.0001). Logistic regression analysis selected preoperative VEGF and CEA serum levels as the only good prognostic indicators of curative and noncurative surgery (P < 0.001; relative risk, 2.98 and 2.03, respectively). Furthermore, VEGF serum levels dropped significantly after surgery, with a further downward trend until the 30th postoperative day (P < 0.001). Stepwise regression analysis selected preoperative VEGF serum level as the only variable associated significantly with the prediction of both disease-specific survival and disease-free survival (P = 0.001).
CONCLUSIONS: Preoperative serum VEGF levels may be useful for predicting outcome in patients with colon carcinoma who undergo surgery. Copyright 2003 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14716760     DOI: 10.1002/cncr.11911

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  40 in total

1.  Evaluation of metastatic and angiogenic potentials of human colon carcinoma cells in chick embryo model systems.

Authors:  M Cecilia Subauste; Tatyana A Kupriyanova; Erin M Conn; Veronica C Ardi; James P Quigley; Elena I Deryugina
Journal:  Clin Exp Metastasis       Date:  2009-10-20       Impact factor: 5.150

2.  Major abdominal surgery increases plasma levels of vascular endothelial growth factor: open more so than minimally invasive methods.

Authors:  Avraham Belizon; Emre Balik; Daniel L Feingold; Marc Bessler; Tracey D Arnell; Kenneth A Forde; Patrick K Horst; Suvinit Jain; Vesna Cekic; Irena Kirman; Richard L Whelan
Journal:  Ann Surg       Date:  2006-11       Impact factor: 12.969

Review 3.  Hepatobiliary surgeons meet immunologists: the case of colorectal liver metastases patients.

Authors:  Matteo Donadon; Nina Cortese; Federica Marchesi; Matteo Cimino; Alberto Mantovani; Guido Torzilli
Journal:  Hepatobiliary Surg Nutr       Date:  2019-08       Impact factor: 7.293

4.  Increased microvascular blood content is an early event in colon carcinogenesis.

Authors:  R K Wali; H K Roy; Y L Kim; Y Liu; J L Koetsier; D P Kunte; M J Goldberg; V Turzhitsky; V Backman
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

5.  Overexpression of ERBB3 promotes proliferation, migration, and angiogenesis in nasopharyngeal carcinoma.

Authors:  Bingyue Duan; Ziyu Zhu; Bo You; Si Shi; Ying Shan; Pan Jiang; Qicheng Zhang; Lili Bao; Yong Yin; Yiwen You
Journal:  Int J Clin Exp Pathol       Date:  2019-08-01

6.  Persistent elevation of plasma vascular endothelial growth factor levels during the first month after minimally invasive colorectal resection.

Authors:  A Belizon; E Balik; P Horst; D Feingold; T Arnell; T Azarani; V Cekic; R Skitt; S Kumara; R L Whelan
Journal:  Surg Endosc       Date:  2008-01-18       Impact factor: 4.584

7.  Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer.

Authors:  Kyung A Kwon; Sung Hyun Kim; Sung Yong Oh; Suee Lee; Jin-Yeong Han; Kyeong Hee Kim; Ri Young Goh; Hong Jo Choi; Ki Jae Park; Mee Sook Roh; Hyo-Jin Kim; Hyuk-Chan Kwon; Jong Hoon Lee
Journal:  BMC Cancer       Date:  2010-05-14       Impact factor: 4.430

8.  Diffusion-weighted MR imaging in liver metastases of colorectal cancer: reproducibility and biological validation.

Authors:  Linda Heijmen; Edwin E G W Ter Voert; Iris D Nagtegaal; Paul Span; Johan Bussink; Cornelis J A Punt; Johannes H W de Wilt; Fred C G J Sweep; Arend Heerschap; Hanneke W M van Laarhoven
Journal:  Eur Radiol       Date:  2012-09-23       Impact factor: 5.315

9.  Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines.

Authors:  M Pia Morelli; Amy M Brown; Todd M Pitts; John J Tentler; Fortunato Ciardiello; Anderson Ryan; Juliane M Jürgensmeier; S Gail Eckhardt
Journal:  Mol Cancer Ther       Date:  2009-09-15       Impact factor: 6.261

10.  Serum vascular endothelial growth factors a, C and d in human breast tumors.

Authors:  Iwona Gisterek; Rafal Matkowski; Aleksandra Lacko; Pawel Sedlaczek; Krzysztof Szewczyk; Przemyslaw Biecek; Agnieszka Halon; Urszula Staszek; Jolanta Szelachowska; Marek Pudelko; Marek Bebenek; Antonina Harlozinska-Szmyrka; Jan Kornafel
Journal:  Pathol Oncol Res       Date:  2009-10-11       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.